Market Outlook Malignant melanoma is the most aggressive and life-...
Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances.......
Market Outlook Biomarker-driven prescribing continues to play an...
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-......
Stage of disease, resectability of the primary tumor, and BRAF-mutation status...
Stage of disease, resectability of the primary tumor, and BRAF-mutation status (in the unresectable or metastatic setting) are key parameters that influence the treatment paradigm of mal......
DRG Epidemiology's coverage of malignant melanoma comprises...
DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of......
Treatment Sequencing provides disease-specific, sequential treatment patterns...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing an......
The malignant melanoma market has become increasingly crowded in recent years...
The malignant melanoma market has become increasingly crowded in recent years with novel treatments expanding therapy options for patients and segmenting the market according to BRAF mutational sta......
The malignant melanoma market in Europe has become crowded. Small-molecule...
The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.&rsquo...
The malignant melanoma therapy market is emerging from a very dynamic period (...
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immu......
DRG Epidemiology's coverage of malignant melanoma comprises...
DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of......
DRG Epidemiology's coverage of malignant melanoma comprises...
DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of......
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
DRG Epidemiology's coverage of malignant melanoma comprises...
DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of......
Treatment Sequencing provides disease-specific, sequential treatment patterns in...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis......
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
Treatment of BRAF-mutation-positive unresectable or metastatic malignant mel...
Treatment of BRAF-mutation-positive unresectable or metastatic malignant mel......
Immune checkpoint inhibitors have entered multiple oncology indications but...
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansio......
The malignant melanoma treatment landscape is dynamic and continues to undergo...
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Three immune checkpoint inhibitors including a dual checkpoint blockade regimen, four BRAF or MEK......
Biomarker-driven prescribing in oncology is playing an increasingly important...
Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSC......
The success of an anticancer therapy is not only dependent on the outcome of...
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and pres...
Since 2011, several novel first-line unresectable or metastatic malignant...
Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK in......
